



20 January 2021

ASX ANNOUNCEMENT

NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT

This notice is given by Cynata Therapeutics Limited (the **Company**) pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company has today issued 1,153,570 fully paid ordinary shares at an issue price of \$0.70 per share (**Shares**) to professional and sophisticated investors in connection with the placement of shortfall shares under a non-renounceable pro rata entitlement offer announced to ASX on 11 December 2020.

Pursuant to paragraph 708A(5)(e) of the Corporations Act, the Company gives notice that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act; and
3. as at the date of this notice, there is no information that is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

Authorised by

A handwritten signature in blue ink, appearing to read "Ross Macdonald", is positioned above the printed name.

Ross Macdonald
Managing Director & CEO

Contacts: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343,
ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, + 315.765.1462,
clacagnina@6degreespr.com